Evidence map›Paper›PMID 40394190›Full record

ArticleNature medicine2025

Cancer treatment paradigms in the precision medicine era.

Vivek Subbiah, Giuseppe Curigliano, Jason K Sicklick, Shumei Kato, Kjetil Tasken, Arielle Medford, Damian T Rieke, Hui-Zi Chen, Adam Wahida, Lars Buschhorn and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Vivek SubbiahSarah Cannon Research Institute, Nashville, Tennessee, USA. viveksubbiah@outlook.com.ORCID http://orcid.org/0000-0002-6064-6837
Giuseppe CuriglianoEuropean Institute of Oncology IRCCS, Milan, Italy.ORCID http://orcid.org/0000-0003-1781-2518
Jason K SicklickMoores Cancer Center, UC San Diego Health, UC San Diego School of Medicine, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-4403-0271
Shumei KatoMoores Cancer Center, UC San Diego Health, UC San Diego School of Medicine, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-1193-1815
Kjetil TaskenInstitute for Cancer Research, Oslo University Hospital and Institute for Clinical Medicine, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0003-2841-4697
Arielle MedfordHarvard Medical School, Boston, MA, USA.
Damian T RiekeDepartment of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin and Comprehensive Cancer Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0003-0027-7977
Hui-Zi ChenMCW Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.
Adam WahidaInstitute of Metabolism and Cell Death, Helmholtz Munich, Neuherberg, Germany.
Lars BuschhornDivision of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Denis HorganEuropean Alliance for Personalised Medicine, Brussels, Belgium.
Razelle KurzrockWIN Consortium, Paris, France.ORCID http://orcid.org/0000-0003-4110-1214

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40394190

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.